Real-time Euronext Paris 11:10:17 2024-03-28 am EDT 5-day change 1st Jan Change
102.6 EUR +1.43% Intraday chart for bioMérieux +2.45% +2.04%
This Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
BioMérieux: FDA approval for multiplex PCR test CF
Berenberg Upgrades BioMérieux to Buy from Hold, Lifts PT MT
BIOMÉRIEUX : Berenberg upgrades its recommendation to 'buy CF
BioMérieux: Invest Securities reiterates its opinion CF
Invest Securities Keeps BioMérieux at Buy, Reduces PT MT
BIOMÉRIEUX : Invest Securities remains positive, reduces its target CF
BIOMERIEUX : Good end to 2023; routine testing dynamics remain intact Alphavalue
Transcript : BioMérieux S.A., 2023 Earnings Call, Mar 14, 2024
BioMérieux S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioMérieux: RNPG down 21% in 2023 CF
SpinChip Diagnostics AS announced that it has received NOK 115 million in funding from bioMérieux S.A. CI
BioMérieux appoints two new members to its Executive Committee CF
BioMérieux Buys Remaining 84% Stake in Canada's Lumed MT
BioMérieux: full acquisition of Lumed CF
BioMérieux S.A. acquired remaining 84% stake in Luméd inc. CI
Invest Securities Lowers BioMérieux's PT, Keeps Buy Rating MT
BIOMERIEUX : Healthy performances across the non-COVID-19 offerings; guidance maintained Alphavalue
Transcript : BioMérieux S.A., Q3 2023 Sales/ Trading Statement Call, Oct 26, 2023
BioMerieux Partners with White Labs to Develop GENE-Up® BrewPRO? Yeast Slurry CI
FTSE 100 Closes Down 1.2% as Sentiment Remains Weak, Rentokil Slips on Disappointing Update DJ
Oxford Nanopore gets bioMerieux backing as announces clinical foray AN
BioMérieux Invests GBP70 Million in Oxford Nanopore Technologies MT
Oxford Nanopore Technologies plc announced that it has received £70 million in funding from bioMérieux S.A. CI
Chinese headwinds could be more severe than expected Alphavalue
Stifel Lifts bioMérieux PT, Maintains Buy Rating MT
Chart bioMérieux
More charts
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.7%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.3%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (31.3%), North America (45.4%), Asia/Pacific (17.4%) and Latin America (5.9%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
101.2 EUR
Average target price
110.6 EUR
Spread / Average Target
+9.34%
Consensus